Page 171 - Traité de Chimie Thérapeutique 4 Médicaments en relation avec des systèmes hormonaux

132 MÉDICAMENTS EN RELA 77ON A VEC DES SYSTÈMES HORMONA UX

Analogues du tolrestat
TAWADA H., SUGIYAMA Y., IKEDA H., YAMAMOTO Y. et MEGUROK., Studies on
antidiabetic agents. IX A new aldose reductase inhibitor, AD-3467 and related 4-
benzoxazine and 1,4-benzothiazine dérivatives : synthesis and biological activity.
Chem. Pharm. Bull. 1990, 38, 1238-1245.
WROBEL J., MILLEN J., SREDY J., DIETRICH A., GORHAM B.J., MALAMAS M.,
KELLY J.M., BAUMAN J.G., HARRISON M.C., JONES L.R., GUINOSSO
C. et SETANJ K., Synthèses of tolrestat analogues containing additional substituent
in the ring and their évaluation as aldose reductase inhibitors. Identification of
potent orally active 2-fluoro dérivatives. J. Med. Chem.,1991, 34, 2504-2520.
MALAMAS M.S. et MILLEN J„ Quinazolineacetic acids and related analogs as aldose
reductase inhibitors. J. Med. Chem., 1991,34, 1492-1503.
MYLARI B.L, LARSON E.R., BEYER T.A., ZEMBROWSKI W.J., ALDINGER C.E., DEE
M.F., SIEGEL T.W. et SINGLETON D.H., Novel potent aldose reductase inhibitor :
3,4-dihydro-4-oxo-3-5-[(trifluoromethyl)-2-benzothiazolyl] methyl-1-phtalazineace-
tic acid (zopolrestat) and congeners ; J. Med. Chem., 1991,34,108-122.
AD-5467, Drugs of the Future, 1991, 16, 13-15.
MYLARI B.M., BEYER T.A., SCOTT P.J., ALDINGER C.E., DEE M.F., SIEGEL
T.W. et ZEMBROWSI W.J., Potent orally active aldose reductase inhibitors related
to zopolrestat : surrogates for benzothiazole side Chain. J. Med. Chem., 1992, 35,
457-465.
MYLARI B.M., ZEMBROWSKI W.J., BEYER T.A., ALDINGER C.E. et SIEGEL T.A.,
Orally active aldose reductase inhibitors : indazoleacetic, oxopyridazineacetic and
oxopyridopyridazineacetic acids. J. Med. Chem., 1992, 35, 2155-2162.
ITOH Y., AO S., NOTSU Y. et HASHIMOTO M., Novel aldose reductase inhibitors :
synthesis and structure-activity studies of (3-benzyl-2,4-dioxo-1,2,3,4-tetrahydro-
quinazolin-1-yl)acetic acids. Drugs ofthe Future, 1992,17, 31-37.
Zenarestat (FR-74366) Drugs of the Future, 1993, 18, 98-99.
Epalrestat
Epalrestat, Drugs ofthe Future, 1987,12, 336-340.
Produits d’origine naturelle
DECK L.M., VANDER JAGT D. L et ROYER R.E., Gossypol and dérivatives : A new
class of aldose reductase inhibitors. J. Med. Chem., 1991, 34, 3301 -3305.
KADOR P.F. et SHARPLESS, Pharmacophor requirements of the aldose reductase
inhibitor site. Mol. Pharmacol., 1983, 24, 521-531.